Remibrutinib Doubles Complete-Response Rates in Phase 3 CIndU Trial
Phase 3 remIND data show remibrutinib 25 mg twice daily achieved complete response in 56.3% of cold urticaria patients, three times placebo, in a demanding provocation-test endpoint.